ClinicalTrials.gg
CompletedNCT05661734Updated Jul 1, 2025Results posted

A Single-arm Study to Evaluate Safety and Effectiveness of VX-548 for Acute Pain

A Phase 3 interventional study of Suzetrigine in Pain, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 14 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-07-01.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
258
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing suzetrigine in Pain — 4 open to participants now, 4 under way, 2 of them phase 3. suzetrigine · Pain.

Enrollment
Largest of 21
258 · median 50
Started
2023
with 3 others
Phase 3
3 of 21
2 open now
Registered
5th of 21
by date
Lead sponsor
15 of 21
Vertex Pharmaceuticals Incorporated

Among the 21 studies testing suzetrigine in Pain, this one has the largest enrollment, is one of 4 that started in 2023, is one of 3 in phase 3, and was the 5th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

Browse Pain studies →

Open to participants now

4 of the 21 studies testing suzetrigine in Pain are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About suzetrigine

suzetrigine: first FDA approval 2025 (JOURNAVX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing suzetrigine in Pain, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and effectiveness of VX-548 in treating acute pain.

03

Conditions studied

  • Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • (BMI) of greater than or equal to (≥) 18.0 to less than (\<) 40.0 kilogram per meter square (kg/m\^2)
  • Non-surgical participants with pain of new origin (not related to a prior known condition) that is moderate or severe on the verbal categorical rating scale (VRS) and ≥4 on the numeric pain rating scale (NPRS)
  • Surgical participants reporting pain at the surgical site that is moderate or severe on the VRS and ≥4 on the NPRS

Key Exclusion Criteria:

  • Surgical participants:

    • History of previous surgery due to the same condition, except for procedures for which a previous surgery on the contra-lateral limb or organ is allowed
    • History of a prior surgical procedure in the same region of the body that resulted in any perioperative complications or that, in the opinion of the investigator or medical monitor, would preclude participation in the study
  • History of any illness or any clinical condition that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the participant

Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
258 participants (actual)

Study arms

  • Experimental
    Suzetrigine (SUZ)

    Participants received SUZ 100 milligram (mg) as first dose, followed by SUZ 50 mg every 12 hours (q12h) for 14 days or until pain resolves, whichever occurs first.

    Drug: Suzetrigine

Interventions

  • Tablets for oral administration.

    Also known as: VX-548, SUZ

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: Day 1 up to Day 30

Secondary outcomes

  1. Percentage of Participants Reporting Good, Very Good, or Excellent on a Patient Global Assessment (PGA) Scale

    The PGA is a single-item assessment of patient perceptions of the method of pain control with the study drug and is evaluated on a 5-point Likert scale as: (poor, fair, good, very good or excellent). Percentage of participants who reported good, very good or excellent on the PGA scale was reported.

    Time frame: Day 14 or at Pain Resolution, whichever occurs first

07

Results

Posted Jul 1, 2025

Participant flow

Participant flow — Overall Study
MilestoneSuzetrigine (SUZ)
Started258
Safety set256
Completed240
Not completed18
Withdrew: Withdrawal of consent (not due to ae)3
Withdrew: Lost to follow-up13
Withdrew: Enrolled but not dosed2

Outcome measures

PrimarySafety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame:
Day 1 up to Day 30
Reported as:
Count of participants · Participants
Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
ParticipantsSuzetrigine (SUZ)
Participants with TEAEs94
Participants with SAEs2
SecondaryPercentage of Participants Reporting Good, Very Good, or Excellent on a Patient Global Assessment (PGA) Scale

The PGA is a single-item assessment of patient perceptions of the method of pain control with the study drug and is evaluated on a 5-point Likert scale as: (poor, fair, good, very good or excellent). Percentage of participants who reported good, very good or excellent on the PGA scale was reported.

Time frame:
Day 14 or at Pain Resolution, whichever occurs first
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Good, Very Good, or Excellent on a Patient Global Assessment (PGA) Scale
percentage of participantsSuzetrigine (SUZ)
Percentage of Participants Reporting Good, Very Good, or Excellent on a Patient Global Assessment (PGA) Scale83.2

Adverse events

Collected over Day 1 up to Day 30. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Suzetrigine (SUZ)0/256 (0%)2/256 (0.8%)18/256 (7%)
Most frequent serious events
Most frequent serious events
EventSuzetrigine (SUZ)
CellulitisInfections and infestations1/256
Suicidal ideationPsychiatric disorders1/256
Most frequent other events
Most frequent other events
EventSuzetrigine (SUZ)
HeadacheNervous system disorders18/256

Baseline characteristics

Baseline data was analyzed based on the Full Analysis Set (FAS), defined as all participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Suzetrigine (SUZ)
Mean43.9 ± 14.1
Sex: Female, Male
Sex: Female, Male(Participants)Suzetrigine (SUZ)
Female173
Male83
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Suzetrigine (SUZ)
Hispanic or Latino108
Not Hispanic or Latino148
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Suzetrigine (SUZ)
White214
Black or African American34
Asian3
American Indian or Alaska Native3
Native Hawaiian or other Pacific Islander1
Multiracial1
08

Study locations

14 sites
  • Anaheim Clinical Trials
    Anaheim, California 92801, United States
  • Trovare Clinical Research | Bakersfield, CA
    Bakersfield, California 93301, United States
  • Mart Medical Research Group LLC
    Miami, Florida 33166, United States
  • Mart Medical Research Group LLC
    South Miami, Florida 33143, United States
  • Atlanta Center for Medical Research | Atlanta, GA
    Atlanta, Georgia 30331, United States
  • Cypress Surgery Center
    Wichita, Kansas 67226, United States
  • OrthoNebraska Hospital
    Omaha, Nebraska 68144, United States
  • Center for Orthopaedic Reconstruction and Excellence
    Jenks, Oklahoma 74037, United States
  • HD Research LLC | First Surgical Hospital
    Bellaire, Texas 77401, United States
  • HD Research LLC | Legent Orthopedic Hospital
    Carrollton, Texas 75006, United States
  • Renovatio Clinical
    Houston, Texas 77380, United States
  • Futuro Clinical Trials
    McAllen, Texas 78501, United States
  • South Texas Spine & Surgical Hospital
    San Antonio, Texas 78258, United States
  • Wasatch Clinical Research
    Salt Lake City, Utah 84107, United States
09

References and documents

Publications

  • Yuan S, Ji H, Lu Y, Zhang Z, Tang H. The Clinical Application of Suzetrigine. J Pain Palliat Care Pharmacother. 2026 Jun;40(2):311-320. doi: 10.1080/15360288.2026.2624502. Epub 2026 Feb 14. PubMed 41689837 ↗
  • McCoun J, Winkle P, Solanki D, Urban J, Bertoch T, Oswald J, Swisher MW, Taber LA, Healey T, Jazic I, Correll DJ, Negulescu PA, Bozic C, Weiner SG; VX-548-107 Study Team. Suzetrigine, a Non-Opioid NaV1.8 Inhibitor With Broad Applicability for Moderate-to-Severe Acute Pain: A Phase 3 Single-Arm Study for Surgical or Non-Surgical Acute Pain. J Pain Res. 2025 Mar 25;18:1569-1576. doi: 10.2147/JPR.S509144. eCollection 2025. PubMed 40165940 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2023 to primary completion in Dec 2023, 11 months.

Results were first posted in Jul 2025, 1 year 6 months after primary completion. A results delay was requested in Dec 2024.

Of 105 industry-sponsored phase 3 interventional studies under Pain, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 23. This study's 11 months is below that.

Counting every sponsor, half of 216 studies reached it within 18 months; a quarter within 9 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2022
First posted
Dec 22, 2022
StartActual
Jan 9, 2023
Primary completionActual
Dec 12, 2023
CompletionActual
Dec 12, 2023
Results delay requested
Dec 9, 2024
Results first posted
Jul 1, 2025
Last update
Jul 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05661734
Responsible party
Sponsor
First posted
Dec 22, 2022
Start date
Jan 9, 2023
Primary completion
Dec 12, 2023
Completion
Dec 12, 2023
Results posted
Jul 1, 2025
Last update
Jul 1, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Suzetrigine

Start the discussion